Ozmosi | Indeglitazar Drug Profile

Product Description

Mechanisms of Action: PPAR-a Agonist, PPAR-d Agonist, PPAR-g Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: Eastern America
Company CEO: Albert Bourla
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Type 2 Diabetes

Phase 1: General Diabetes|Healthy Volunteers

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Latest Trial Update Date	Data Updated
NCT00447629	3180A1-1109	P1	Completed	General Diabetes\|Healthy Volunteers	None	2019-03-21	Treatments
NCT00448032	3180A1-107	P1	Completed	Healthy Volunteers\|General Diabetes	None	2019-03-21	Treatments
2006-003897-87	2006-003897-87	P2	Completed	Type 2 Diabetes	2009-01-19	2022-03-12	Treatments
2005-004227-19	2005-004227-19	P2	Completed	Type 2 Diabetes	2007-02-08	2022-03-12	Treatments
NCT00425919	3180A1-200	P2	Terminated	Type 2 Diabetes	None	2019-03-21	Treatments

Recent News Events

Date	Type	Title
12/15/2023	PubMed	Design, synthesis, and biological evaluation of deuterated indolepropionic acid derivatives as novel long-acting pan PPARα/γ/δ agonists.
02/06/2023	PubMed	Quercetin ameliorates hepatic fat accumulation in high-fat diet-induced obese mice via PPARs.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Indeglitazar

Alternative Names: indeglitazar, ppm-204, ppm204, ppm 204 Clinical Status: Inactive Latest Update: 2023-12-15 Latest Update Note: PubMed Publication